deltatrials
Active Not Recruiting PHASE4 INTERVENTIONAL 2-arm NCT04340076

Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis (BeNeBio)

Dose Reduction of the New Generation Biologicals (IL17 and IL23 Inhibitors) in Psoriasis: A Pragmatic, Multicentre, Randomized, Controlled, Non-inferiority Study - BeNeBio Study

Sponsor: Belgium Health Care Knowledge Centre

Conditions Psoriasis Psoriasis Vulgaris
Interventions Bimekizumab Brodalumab Guselkumab Ixekizumab Risankizumab Secukinumab Tildrakizumab
Updated 14 times since 2020 Last updated: Sep 4, 2025 Started: Aug 20, 2020 Primary completion: Dec 31, 2025 Completion: Dec 31, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Psoriasis and Psoriasis Vulgaris and is currently ongoing. Belgium Health Care Knowledge Centre leads this study, which shows 14 recorded versions since 2020 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~May 2020 – ~Oct 2020 · 5 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Sep 2021 · 6 months · monthly snapshot~Sep 2021 – ~Dec 2021 · 3 months · monthly snapshot~Dec 2021 – ~Mar 2022 · 3 months · monthly snapshot~Mar 2022 – ~Sep 2022 · 6 months · monthly snapshot~Sep 2022 – ~Jan 2023 · 4 months · monthly snapshot~Jan 2023 – ~Feb 2024 · 13 months · monthly snapshot~Feb 2024 – ~Jul 2024 · 5 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – ~Oct 2025 · 30 days · monthly snapshot~Oct 2025 – present · 11 months · monthly snapshot

Change History

14 versions recorded

  1. Oct 2025 — Present [monthly]

    Active Not Recruiting PHASE4

  2. Sep 2025 — Oct 2025 [monthly]

    Active Not Recruiting PHASE4

  3. Sep 2024 — Sep 2025 [monthly]

    Active Not Recruiting PHASE4

  4. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE4

  5. Feb 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE4

    Status: Recruiting → Active Not Recruiting

▶ Show 9 earlier versions

  1. Jan 2023 — Feb 2024 [monthly]

    Recruiting PHASE4

  2. Sep 2022 — Jan 2023 [monthly]

    Recruiting PHASE4

  3. Mar 2022 — Sep 2022 [monthly]

    Recruiting PHASE4

  4. Dec 2021 — Mar 2022 [monthly]

    Recruiting PHASE4

  5. Sep 2021 — Dec 2021 [monthly]

    Recruiting PHASE4

  6. Mar 2021 — Sep 2021 [monthly]

    Recruiting PHASE4

  7. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE4

  8. Oct 2020 — Jan 2021 [monthly]

    Recruiting PHASE4

    Status: Not Yet Recruiting → Recruiting

  9. May 2020 — Oct 2020 [monthly]

    Not Yet Recruiting PHASE4

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Belgium Health Care Knowledge Centre
  • Radboud University Medical Center
  • University Hospital, Ghent
  • ZonMw: The Netherlands Organisation for Health Research and Development
Data source: Radboud University Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Almelo, Netherlands , Bergen op Zoom, Netherlands , Breda, Netherlands , Brussels, Belgium , Doetinchem, Netherlands , Eindhoven, Netherlands , Ghent, Belgium , Groningen, Netherlands , Leuven, Belgium , Liège, Belgium and 6 more locations